Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Prolia for GIOP in Men and Women

FirstWord Pharma news release; 2018 May 21

Amgen recently announced that the US Food and Drug Administration (FDA) has approved the use of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. This approval is based on data from a Phase 3 study which showed patients on glucocorticoid therapy who received Prolia had greater gains in bone mineral density (BMD) compared to those who received active comparator (risedronate). Amgen is headquartered in Thousand Oaks, CA.

Dosage/administration: Pregnancy must be ruled out prior to administration of Prolia. Prolia should be administered by a healthcare professional and the recommended dosage is 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen. Patients should be instructed to take calcium 1,000 mg daily and at least 400 IU vitamin D daily.

Adverse reactions: With GIOP, the most common adverse reactions (> 3% and more common than active-control group) were back pain, hypertension, bronchitis, and headache.

Citation:

FDA approves Prolia (denosumab) for glucocorticoid-induced osteoporosis. [news release]. Thousand Oaks, CA: Amgen. May 21, 2018. https://www.firstwordpharma.com/node/1567150. Accessed May 31, 2018.

This Week's Must Reads

Inverse U-Shaped Link Between CRP, Systolic BP in RA, Arthritis Res Ther; 2018 Jun 1; Yu, Kim, Vanni, et al

Exercise Linked with Protective CV Risk in RA , J Clin Rheumatol; 2018 ePub May 25; Byram, et al

No Link Between Coffee Consumption and Incident RA, J Clin Rheumatol; ePub 2018 Apr 19; Lamichhane, et al

PROMIS Forms Capture Fatigue Experience in RA, Qual Life Res; ePub 2018 May 24; Bartlett, et al

MBDA Score Independently Predictive of Relapsing RA, PLoS One; ePub 2018 May 23; Moghadam, et al

Must Reads in FDA Actions

FDA Approves Prolia for GIOP in Men and Women, FirstWord Pharma news release; 2018 May 21

FDA Approves Xeljanz/Xeljanz XR for Adult PsA, Pfizer news release; 2017 Dec 14

FDA Approves New Pfizer Biosimilar Ixifi, Pfizer news release; 2017 Dec 13

FDA Approves Taltz for Adult Psoriatic Arthritis, FirstWord Pharma news release; 2017 Dec 1

FDA Approves Zilretta for OA Knee Pain, Flexion Therapeutics news release; 2017 Oct 6